CVS Health Corp vs Oracle Corporation — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Oracle Corporation trades at $137.47 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 3.7× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Oracle Corporation for 72 Days on average.
| CVS | ORCL | |
|---|---|---|
Market Cap | $112.29B | $411.34B |
Volume | 7,763,676 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $110.60 | $313.00 |
52-Week Low | $70.08 | $114.99 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $174.64B | $535.15B |
Dividend Yield | 3.03% | 1.47% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Oracle (ORCL) is trading at $135.56, down 6.36% over the past 24 hours amid broader market concerns about AI spending cycles and higher borrowing costs. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust revenue growth of 21.67% net income margin for 2025. Technical indicators signal bearish momentum with the price below key resistance levels, while analyst sentiment remains overwhelmingly positive with a $236.52 consensus price target representing significant upside potential.
Oracle presents a compelling investment opportunity with strong AI cloud demand driving 120% infrastructure growth, though near-term headwinds include market volatility and aggressive capital expenditure. The company's improving debt-to-asset ratio and consistent earnings growth support long-term value, but investors should monitor execution risks in the competitive cloud infrastructure space and potential macroeconomic pressures on tech valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →